Schroder Investment Management Group Sells 9,933,836 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Schroder Investment Management Group lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 99.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,503 shares of the biopharmaceutical company's stock after selling 9,933,836 shares during the quarter. Schroder Investment Management Group owned 0.07% of Halozyme Therapeutics worth $4,199,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Venturi Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics in the 4th quarter worth about $69,000. Retirement Systems of Alabama increased its holdings in Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock worth $22,282,000 after buying an additional 74,173 shares in the last quarter. Shaker Investments LLC OH increased its holdings in Halozyme Therapeutics by 12.3% in the 4th quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock worth $3,601,000 after buying an additional 8,249 shares in the last quarter. Foster & Motley Inc. increased its holdings in Halozyme Therapeutics by 118.6% in the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock worth $1,113,000 after buying an additional 12,630 shares in the last quarter. Finally, Jennison Associates LLC bought a new stake in Halozyme Therapeutics in the 4th quarter worth about $731,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several research firms recently commented on HALO. Benchmark reiterated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $62.78.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the transaction, the director now directly owns 33,108 shares of the company's stock, valued at approximately $2,120,567.40. The trade was a 1.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,200 shares of company stock valued at $1,286,568. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded down $1.72 during mid-day trading on Thursday, reaching $58.93. 174,987 shares of the company traded hands, compared to its average volume of 1,399,762. The company's 50 day moving average price is $60.12 and its 200-day moving average price is $54.89. The firm has a market cap of $7.28 billion, a PE ratio of 17.18, a PEG ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.